| Literature DB >> 371801 |
M E Lau, H H Hansen, N I Nissen, H Pedersen.
Abstract
A new oral form of VP-16-213 consisting of a hydrophilic soft gelatin capsule containing a VP-16-213 solution was tested for toxicity in 26 patients. The drug was administered at four different dose levels, 350, 500, 650, and 750 mg/m2, in 5-day courses every 21-28 days. A dose-dependent effect was observed with regard to hematologic toxicity and alopecia. It is concluded that the drinking ampules of VP-16-213 can be replaced with the new oral capsules with a recommended initial dose of 100-130 mg/m2 given in 5-day courses every 21-28 days.Entities:
Mesh：
Substances：
Year: 1979 PMID： 371801
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960